Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Trial of Ripasudil Eye Drops for Retinopathy of Prematurity
jRCT2071200047Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ripasudil in retinopathy of prematurity (ROP), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Proportion of patients with adverse events and adverse drug reactions. Started Nov 2020; status: completed.
02
Drugs
ripasudil
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on jRCT2071200047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200047.